Status:

COMPLETED

Growth and Safety Clinical Trial on a New Infant Formula.

Lead Sponsor:

Nara Organics

Collaborating Sponsors:

Paidion Research, Inc.

Conditions:

Healthy Growth

Eligibility:

All Genders

1-14 years

Phase:

NA

Brief Summary

The aim of the study is to assess age-appropriate growth of healthy infants fed a new organic milk-based infant formula.

Detailed Description

A 16-weeks length, randomized, controlled, double-blind, parallel study designed to evaluate growth and tolerance of healthy infants fed milk-based infant formula. The study has been designed in accor...

Eligibility Criteria

Inclusion

  • Healthy gestational term (≥ 37 wks; ≤ 41 wks and 6 days).
  • Birth weight of ≥ 2,500 g and ≤ 4,500 g.
  • Postnatal age ≤ 14 days.
  • Singleton.
  • Designated as healthy, that is no recognized diseases.
  • Weight, length, weight-for-length, and head circumference within ≥ 5th and ≤ 95th percentile for age-sex according to World Health Organization (WHO) growth standards (birth to 24 months).
  • Exclusive feeding and tolerating cow milk formula at time of enrollment.
  • Parent(s) or legal guardians are willing and able to feed the assigned formula as sole source of nutrition.
  • Parent(s) or legal guardians are willing and able to participate in anthropometric procedures.
  • Parent(s) or legal guardians have voluntarily signed and dated required participation forms, such as the ICF approved by an IRB.

Exclusion

  • An infant from a multiple birth, such as twin, triplet, or the like.
  • Personal or immediate family history of cow-milk protein allergy or intolerance.
  • Currently on any medication to treat growth failure or that may significantly impact growth.
  • Evidence of any anatomic and/or physiologic condition that would interfere with normal growth, development, or feeding, such as genetic, neurological, gastrointestinal, cardiac, pulmonary, hepatic, or renal.
  • A maternal history with known adverse effects on the fetus and/or the newborn infant, such as positive HIV, insulin-dependent diabetes, opioid exposure during pregnancy.
  • Enrolled in another clinical trial involving a drug, nutrition supplement, device, or intervention.

Key Trial Info

Start Date :

February 12 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 12 2022

Estimated Enrollment :

176 Patients enrolled

Trial Details

Trial ID

NCT04671576

Start Date

February 12 2021

End Date

August 12 2022

Last Update

September 28 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

TeleResearch Hub

Cary, North Carolina, United States, 27519